drugset
drugset / Trial / NCT07814339

Hydrochloroquinine & Decitabine With Venetoclax in AML

NCT07814339 ↗

Phase 1 Not yet recruiting 18 enrolled Rutgers, The State University of New Jersey
NaSingle-groupOpen-labelTreatment

Summary

Phase I: Primary Objective: \- Determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of the o-Dec, ven, and HCQ Secondary Objectives: * Characterize the safety profile of the triplet * Estimate the efficacy of the combination to induce remission

Timeline

Start
2026-09
Primary completion
2028-06
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine/cedazuridine Unknown — Oral
Subject Hydroxychloroquine Small molecule — Oral
Subject Venetoclax Small molecule — Oral

Indications

acute myeloid leukemia